Enhanced in vitro formation and antibiotic resistance of nonattached pseudomonas aeruginosa aggregates through incorporation of neutrophil products

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 11, 2014, Pages 6851-6860

  Caceres, Silvia M ^a   Malcolm, Kenneth C ^a,c   Taylor Cousar, Jennifer L ^a,c   Nichols, David P ^a,b,c   Saavedra, Milene T ^a,c   Bratton, Donna L ^b   Moskowitz, Samuel M ^d   Burns, Jane L ^e   Nick, Jerry A ^a,c  

^a Departments of Pediatrics   (United States)

^b DEPARTMENT OF MEDICINE   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; DEOXYRIBONUCLEASE; TOBRAMYCIN; ANTIINFECTIVE AGENT; LASA PROTEIN, PSEUDOMONAS AERUGINOSA; METALLOPROTEINASE; VIRULENCE FACTOR;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BIOFILM; CONTROLLED STUDY; DISPERSION; DRUG ANTAGONISM; EXTRACELLULAR FLUID; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; INOCULATION; NEUTROPHIL; NONHUMAN; PH; PSEUDOMONAS AERUGINOSA; QUORUM SENSING; SPUTUM; BIOSYNTHESIS; COMPLICATION; CYSTIC FIBROSIS; DRUG EFFECTS; GENETICS; IMMUNOLOGY; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANCE; PSEUDOMONAS INFECTION;

ANTI-BACTERIAL AGENTS; AZITHROMYCIN; BIOFILMS; CYSTIC FIBROSIS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; METALLOPROTEASES; MICROBIAL SENSITIVITY TESTS; NEUTROPHILS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; QUORUM SENSING; SPUTUM; TOBRAMYCIN; VIRULENCE FACTORS;

EID: 84908592670     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03514-14     Document Type: Article

References (62)

1. Khan TZ, Wagener JS, Bost T, Martinez J, Accurso FJ, Riches DW. 1995. Early pulmonary inflammation in infants with cystic fibrosis. Am. J. Respir. Crit. Care Med. 151:1075-1082. http://dx.doi.org/10.1164/ajrccm.151.4.7697234.
2. Burns JL, Gibson RL, McNamara S, Yim D, Emerson J, Rosenfeld M, Hiatt P, McCoy K, Castile R, Smith AL, Ramsey BW. 2001. Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis. J. Infect. Dis. 183:444-452. http://dx.doi.org/10.1086/318075.
3. Rosenfeld M, Gibson RL, McNamara S, Emerson J, Burns JL, Castile R, Hiatt P, McCoy K, Wilson CB, Inglis A, Smith A, Martin TR, Ramsey BW. 2001. Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis. Pediatr. Pulmonol. 32:356-366. http://dx.doi.org/10.1002/ppul.1144.
4. Frederiksen B, Koch SLC, Hoiby N. 1996. Improved survival in the Danish center-treated CF patients: results of aggressive treatment. Pediatr. Pulmonol. 21:153-158. http://dx.doi.org/10.1002/(SICI)1099-0496(199 603)21:3-153::AID-PPUL1-3.0.CO;2-R.
5. Cystic Fibrosis Foundation. 2013. Cystic Fibrosis Foundation patient registry. 2012 annual data report to the center directors. Cystic Fibrosis Foundation, Bethesda, MD.
6. Singh PK, Schaefer AL, Parsek MR, Moninger TO, Welsh MJ, Greenberg EP. 2000. Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms. Nature 407:762-764. http://dx.doi.org/10.1038/35037627.
7. Aaron SD, Ferris W, Ramotar K, Vandemheen K, Chan F, Saginur R. 2002. Single and combination antibiotic susceptibilities of planktonic, adherent, and biofilm-grown Pseudomonas aeruginosa isolates cultured from sputa of adults with cystic fibrosis. J. Clin. Microbiol. 40:4172-4179. http://dx.doi.org/10.1128/JCM.40.11.4172-4179.2002.
8. Drenkard E, Ausubel FM. 2002. Pseudomonas biofilm formation and antibiotic resistance are linked to phenotypic variation. Nature 416:740-743. http://dx.doi.org/10.1038/416740a.
9. Lam J, Chan R, Lam K, Costerton JW. 1980. Production of mucoid microcolonies by Pseudomonas aeruginosa within infected lungs in cystic fibrosis. Infect. Immun. 28:546-556.
10. Bjarnsholt T, Jensen PO, Fiandaca MJ, Pedersen J, Hansen CR, Andersen CB, Pressler T, Givskov M, Hoiby N. 2009. Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients. Pediatr. Pulmonol. 44:547-558. http://dx.doi.org/10.1002/ppul.21011.
11. Worlitzsch D, Tarran R, Ulrich M, Schwab U, Cekici A, Meyer KC, Birrer P, Bellon G, Berger J, Weiss T, Botzenhart K, Yankaskas JR, Randell S, Boucher RC, Doring G. 2002. Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J. Clin. Invest. 109:317-325. http://dx.doi.org/10.1172/JCI13870.
12. Perks B, Shute JK. 2000. DNA and actin bind and inhibit interleukin-8 function in cystic fibrosis sputa: in vitro effects of mucolytics. Am. J. Respir. Crit. Care Med. 162:1767-1772. http://dx.doi.org/10.1164/ajrccm.162.5.9908107.
13. Sheils CA, Kas J, Travassos W, Allem PG, Janmey PA, Wohl ME, Stossel TP. 1996. Actin filaments mediate DNA fiber formation in chronic inflammatory airway disease. Am. J. Pathol. 148:919-927.
14. Lethem MI, James SL, Marriott C, Burke JF. 1990. The origin of DNA associated with mucus glycoproteins in cystic fibrosis sputum. Eur. Respir. J. 3:19-23.
15. Roum JH, Buhl R, McElvaney NG, Borok Z, Crystal RG. 1993. Systemic deficiency of glutathione in cystic fibrosis. J. Appl. Physiol. 75:2419-2424.
16. Balfour-Lynn IM. 1999. The protease-antiprotease battle in the cystic fibrosis lung. J. R Soc. Med. 92(Suppl 37):S23-S30.
17. Sagel SD, Sontag MK, Accurso FJ. 2009. Relationship between antimicrobial proteins and airway inflammation and infection in cystic fibrosis. Pediatr. Pulmonol. 44:402-409. http://dx.doi.org/10.1002/ppul.21028.
18. Lee A, Whyte MKB, Haslett C. 1993. Inhibition of apoptosis and prolongation of neutrophil functional longevity by inflammatory mediators. J. Leukocyte Biol. 54:283-288.
19. Edwards SW, Moulding DA, Derouet M, Moots RJ. 2003. Regulation of neutrophil apoptosis, p 204-224. In Cassatella MA (ed), The neutrophil, vol 83 Karger, Berlin, Germany.
20. Walker TS, Worthen GS, Poch KR, Lieber JG, Saavedra MT, Malcolm KC, Fessler MB, Vasil ML, Nick JA. 2005. Enhanced Pseudomonas aeruginosa biofilm development mediated by human neutrophils. Infect. Immun. 73:3693-3701. http://dx.doi.org/10.1128/IAI.73.6.3693-3701.2005.
21. Robertson DM, Parks QM, Young RL, Kret J, Poch KR, Malcolm KC, Nichols DP, Nichols M, Zhu M, Cavanagh HD, Nick JA. 2010. Disruption of contact lens-associated Pseudomonas aeruginosa biofilms formed in the presence of neutrophils. Invest. Ophthalmol. Vis. Sci. 52:2844-2850. http://dx.doi.org/10.1167/iovs.10-6469.
22. Parks QM, Young RL, Poch KR, Malcolm KC, Vasil ML, Nick JA. 2009. Neutrophil enhancement of Pseudomonas aeruginosa biofilm development: human F-actin and DNA as targets for therapy. J. Med. Microbiol. 58:492-502. http://dx.doi.org/10.1099/jmm.0.005728-0.
23. Tang JX, Wen Q, Bennett A, Kim B, Sheils CA, Bucki R, Janmey PA. 2005. Anionic poly(amino acid)s dissolve F-actin and DNA bundles, enhance DNase activity, and reduce the viscosity of cystic fibrosis sputum. Am. J. Physiol. Lung Cell. Mol. Physiol. 289:L599-L605. http://dx.doi.org/10.1152/ajplung.00061.2005.
24. Bjarnsholt T, Alhede M, Alhede M, Eickhardt-Sorensen SR, Moser C, Kuhl M, Jensen PO, Hoiby N. 2013. The in vivo biofilm. Trends Microbiol. 21:466-474. http://dx.doi.org/10.1016/j.tim.2013.06.002.
25. Young RL, Malcolm KC, Kret JE, Caceres SM, Poch KR, Nichols DP, Taylor-Cousar JL, Saavedra MT, Randell SH, Vasil ML, Burns JL, Moskowitz SM, Nick JA. 2011. Neutrophil extracellular trap (NET)-mediated killing of Pseudomonas aeruginosa: evidence of acquired resistance within the CF airway, independent of CFTR. PLoS One 6:e23637. http://dx.doi.org/10.1371/journal.pone.0023637.
26. Haslett C, Guthrie LA, Kopaniak M, Johnston RB, Jr, Henson PM. 1985. Modulation of multiple neutrophil functions by trace amounts of bacterial LPS and by preparative methods. Am. J. Pathol. 119:101-110.
27. Ruddy J, Emerson J, Moss R, Genatossio A, McNamara S, Burns JL, Anderson G, Rosenfeld M. 2013. Sputum tobramycin concentrations in cystic fibrosis patients with repeated administration of inhaled tobramycin. J. Aerosol Med. Pulm. Drug Deliv. 26:69-75. http://dx.doi.org/10.1089/jamp.2011.0942.
28. Wilms EB, Touw DJ, Heijerman HG. 2006. Pharmacokinetics of azithromycin in plasma, blood, polymorphonuclear neutrophils and sputum during long-term therapy in patients with cystic fibrosis. Ther. Drug Monit. 28:219-225. http://dx.doi.org/10.1097/01.ftd.0000195617.69721.a5.
29. Cystic Fibrosis Therapeutics Development Network Coordinating Center. 2013. Sputum processing for cytology and inflammatory markers: SOP 508. Cystic Fibrosis Therapeutics Development Network Coordinating Center, Bethesda, MD.
30. Rasband WS. 2012. ImageJ. U.S. National Institutes of Health, Bethesda, MD. http://imagej.nih.gov/ij/.
31. Savli H, Karadenizli A, Kolayli F, Gundes S, Ozbek U, Vahaboglu H. 2003. Expression stability of six housekeeping genes: a proposal for resistance gene quantification studies of Pseudomonas aeruginosa by real-time quantitative RT-PCR. J. Med. Microbiol. 52:403-408. http://dx.doi.org/10.1099/jmm.0.05132-0.
32. Sauer K, Camper AK, Ehrlich GD, Costerton JW, Davies DG. 2002. Pseudomonas aeruginosa displays multiple phenotypes during development as a biofilm. J. Bacteriol. 184:1140-1154. http://dx.doi.org/10.1128/jb.184.4.1140-1154.2002.
33. Whiteley M, Bangera MG, Bumgarner RE, Parsek MR, Teitzel GM, Lory S, Greenberg EP. 2001. Gene expression in Pseudomonas aeruginosa biofilms. Nature 413:860-864. http://dx.doi.org/10.1038/35101627.
34. Musken M, Di Fiore S, Dotsch A, Fischer R, Haussler S. 2010. Genetic determinants of Pseudomonas aeruginosa biofilm establishment. Microbiology 156:431-441. http://dx.doi.org/10.1099/mic.0.033290-0.
35. Lee CS, Wetzel K, Buckley T, Wozniak D, Lee J. 2011. Rapid and sensitive detection of Pseudomonas aeruginosa in chlorinated water and aerosols targeting gyrB gene using real-time PCR. J. Appl. Microbiol. 111: 893-903. http://dx.doi.org/10.1111/j.1365-2672.2011.05107.x.
36. Baltimore RS, Christie CD, Smith GJ. 1989. Immunohistopathologic localization of Pseudomonas aeruginosa in lungs from patients with cystic fibrosis. Implications for the pathogenesis of progressive lung deterioration. Am. Rev. Resp. Dis. 140:1650-1661.
37. Kirov SM, Webb JS, O'May CY, Reid DW, Woo JK, Rice SA, Kjelleberg S. 2007. Biofilm differentiation and dispersal in mucoid Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Microbiology 153: 3264-3274. http://dx.doi.org/10.1099/mic.0.2007/009092-0.
38. Lequette Y, Greenberg EP. 2005. Timing and localization of rhamnolipid synthesis gene expression in Pseudomonas aeruginosa biofilms. J. Bacteriol. 187:37-44. http://dx.doi.org/10.1128/JB.187.1.37-44.2005.
39. Stewart PS, Costerton JW. 2001. Antibiotic resistance of bacteria in biofilms. Lancet 358:135-138. http://dx.doi.org/10.1016/S0140-6736(01)05321-1.
40. Mah TF, Pitts B, Pellock B, Walker GC, Stewart PS, O'Toole GA. 2003. A genetic basis for Pseudomonas aeruginosa biofilm antibiotic resistance. Nature 426:306-310. http://dx.doi.org/10.1038/nature02122.
41. Nichols DP, Caceres S, Caverly L, Fratelli C, Kim SH, Malcolm K, Poch KR, Saavedra M, Solomon G, Taylor-Cousar J, Moskowitz S, Nick JA. 2013. Effects of azithromycin in Pseudomonas aeruginosa burn wound infection. J. Surg. Res. 183:767-776. http://dx.doi.org/10.1016/j.jss.2013.02.003.
42. Tre-Hardy M, Nagant C, El Manssouri N, Vanderbist F, Traore H, Vaneechoutte M, Dehaye JP. 2010. Efficacy of the combination of tobramycin and a macrolide in an in vitro Pseudomonas aeruginosa mature biofilm model. Antimicrob. Agents Chemother. 54:4409-4415. http://dx.doi.org/10.1128/AAC.00372-10.
43. Dales L, Ferris W, Vandemheen K, Aaron SD. 2009. Combination antibiotic susceptibility of biofilm-grown Burkholderia cepacia and Pseudomonas aeruginosa isolated from patients with pulmonary exacerbations of cystic fibrosis. Eur. J. Clin. Microbiol. Infect. Dis. 28:1275-1279. http://dx.doi.org/10.1007/s10096-009-0774-9.
44. Nick JA, Moskowitz SM, Chmiel JF, Forssen AV, Kim SH, Saavedra MT, Saiman L, Taylor-Cousar JL, Nichols DP. 2014. Azithromycin may antagonize inhaled tobramycin when targeting P. aeruginosa in cystic fibrosis. Ann. Am. Thorac. Soc. 11:342-350. http://dx.doi.org/10.1513/AnnalsATS.201310-352OC.
45. O'Toole GA, Kolter R. 1998. Initiation of biofilm formation in Pseudomonas fluorescens WCS365 proceeds via multiple, convergent signalling pathways: a genetic analysis. Mol. Microbiol. 28:449-461. http://dx.doi.org/10.1046/j.1365-2958.1998.00797.x.
46. Ceri H, Olson ME, Stremick C, Read RR, Morck D, Buret A. 1999. The Calgary biofilm device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J. Clin. Microbiol. 37:1771-1776.
47. Pamp SJ, Sternberg C, Tolker-Nielsen T. 2009. Insight into the microbial multicellular lifestyle via flow-cell technology and confocal microscopy. Cytometry A 75:90-103. http://dx.doi.org/10.1002/cyto.a.20685.
48. Christensen BB, Sternberg C, Andersen JB, Palmer RJ, Jr, Nielsen AT, Givskov M, Molin S. 1999. Molecular tools for study of biofilm physiology. Methods Enzymol. 310:20-42. http://dx.doi.org/10.1016/S0076-6879(99)10004-1.
49. Anderl JN, Franklin MJ, Stewart PS. 2000. Role of antibiotic penetration limitation in Klebsiella pneumoniae biofilm resistance to ampicillin and ciprofloxacin. Antimicrob. Agents Chemother. 44:1818-1824. http://dx.doi.org/10.1128/AAC.44.7.1818-1824.2000.
50. Zelver N, Hamilton M, Pitts B, Goeres D, Walker D, Sturman P, Heersink J. 1999. Measuring antimicrobial effects on biofilm bacteria: from laboratory to field. Methods Enzymol. 310:608-628. http://dx.doi.org/10.1016/S0076-6879(99)10047-8.
51. Goeres DM, Hamilton MA, Beck NA, Buckingham-Meyer K, Hilyard JD, Loetterle LR, Lorenz LA, Walker DK, Stewart PS. 2009. A method for growing a biofilm under low shear at the air-liquid interface using the drip flow biofilm reactor. Nat. Protoc. 4:783-788. http://dx.doi.org/10.1038/nprot.2009.59.
52. Schleheck D, Barraud N, Klebensberger J, Webb JS, McDougald D, Rice SA, Kjelleberg S. 2009. Pseudomonas aeruginosa PAO1 preferentially grows as aggregates in liquid batch cultures and disperses upon starvation. PLoS One 4:e5513. http://dx.doi.org/10.1371/journal.pone.0005513.
53. Lopez-Boado YS, Espinola M, Bahr S, Belaaouaj A. 2004. Neutrophil serine proteinases cleave bacterial flagellin, abrogating its host responseinducing activity. J. Immunol. 172:509-515. http://dx.doi.org/10.4049/jimmunol.172.1.509.
54. Staudinger BJ, Muller JF, Halldorsson S, Boles B, Angermeyer A, Nguyen D, Rosen H, Baldursson O, Gottfreethsson M, Guethmundsson GH, Singh PK. 2014. Conditions associated with the cystic fibrosis defect promote chronic Pseudomonas aeruginosa infection. Am. J. Respir. Crit. Care Med. 189:812-824. http://dx.doi.org/10.1164/rccm.201312-2142OC.
55. Malcolm KC, Nichols EM, Caceres SM, Kret JE, Martiniano SL, Sagel SD, Chan ED, Caverly L, Solomon GM, Reynolds P, Bratton DL, Taylor-Cousar JL, Nichols DP, Saavedra MT, Nick JA. 2013. Mycobac-terium abscessus induces a limited pattern of neutrophil activation that promotes pathogen survival. PLoS One 8:e57402. http://dx.doi.org/10.1371/journal.pone.0057402.
56. Luzar MA, Thomassen MJ, Montie TC. 1985. Flagella and motility alterations in Pseudomonas aeruginosa strains from patients with cystic fibrosis: relationship to patient clinical condition. Infect. Immun. 50:577-582.
57. Cabrol S, Olliver A, Pier GB, Andremont A, Ruimy R. 2003. Transcription of quorum-sensing system genes in clinical and environmental isolates of Pseudomonas aeruginosa. J. Bacteriol. 185:7222-7230. http://dx.doi.org/10.1128/JB.185.24.7222-7230.2003.
58. Smith EE, Buckley DG, Wu Z, Saenphimmachak C, Hoffman LR, D'Argenio DA, Miller SI, Ramsey BW, Speert DP, Moskowitz SM, Burns JL, Kaul R, Olson MV. 2006. Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients. Proc. Natl. Acad. Sci. U. S. A. 103:8487-8492. http://dx.doi.org/10.1073/pnas.0602138103.
59. Schaber JA, Triffo WJ, Suh SJ, Oliver JW, Hastert MC, Griswold JA, Auer M, Hamood AN, Rumbaugh KP. 2007. Pseudomonas aeruginosa forms biofilms in acute infection independent of cell-to-cell signaling. Infect. Immun. 75:3715-3721. http://dx.doi.org/10.1128/IAI.00586-07.
60. Sriramulu DD, Lunsdorf H, Lam JS, Romling U. 2005. Microcolony formation: a novel biofilm model of Pseudomonas aeruginosa for the cystic fibrosis lung. J. Med. Microbiol. 54:667-676. http://dx.doi.org/10.1099/jmm.0 .45969-0.
61. Shak S, Capon DJ, Hellmiss R, Marsters SA, Baker CL. 1990. Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum. Proc. Natl. Acad. Sci. U. S. A. 87:9188-9192. http://dx.doi.org/10.1073/pnas.87.23.9188.
62. Hunt BE, Weber A, Berger A, Ramsey B, Smith AL. 1995. Macromolecular mechanisms of sputum inhibition of tobramycin activity. Antimicrob. Agents Chemother. 39:34-39. http://dx.doi.org/10.1128/AAC.39.1.34.